Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria
Joachim Pietz, … , Chris Boesch, Hans Joachim Bremer
Joachim Pietz, … , Chris Boesch, Hans Joachim Bremer
Published April 15, 1999
Citation Information: J Clin Invest. 1999;103(8):1169-1178. https://doi.org/10.1172/JCI5017.
View: Text | PDF
Article

Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria

  • Text
  • PDF
Abstract

Large neutral amino acids (LNAAs), including phenylalanine (Phe), compete for transport across the blood-brain barrier (BBB) via the L-type amino acid carrier. Accordingly, elevated plasma Phe impairs brain uptake of other LNAAs in patients with phenylketonuria (PKU). Direct effects of elevated brain Phe and depleted LNAAs are probably major causes for disturbed brain development and function in PKU. Competition for the carrier might conversely be put to use to lower Phe influx when the plasma concentrations of all other LNAAs are increased. This hypothesis was tested by measuring brain Phe in patients with PKU by quantitative 1H magnetic resonance spectroscopy during an oral Phe challenge with and without additional supplementation with all other LNAAs. Baseline plasma Phe was ∼1,000 μmol/l and brain Phe was ∼250 μmol/l in both series. Without LNAA supplementation, brain Phe increased to ∼400 μmol/l after the oral Phe load. Electroencephalogram (EEG) spectral analysis revealed acutely disturbed brain activity. With concurrent LNAA supplementation, Phe influx was completely blocked and there was no slowing of EEG activity. These results are relevant for further characterization of the LNAA carrier and of the pathophysiology underlying brain dysfunction in PKU and for treatment of patients with PKU, as brain function might be improved by continued LNAA supplementation.

Authors

Joachim Pietz, Roland Kreis, André Rupp, Ertan Mayatepek, Dietz Rating, Chris Boesch, Hans Joachim Bremer

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Downfield portion of the 1H-MR spectrum. (a) Spectrum of a 26-year-old p...
Downfield portion of the 1H-MR spectrum. (a) Spectrum of a 26-year-old patient with PKU. (b) The averaged spectrum of 10 healthy age-matched subjects, and (c) the corresponding spectrum of an aqueous solution of Phe. The right side illustrates the model-fitting procedure used. Spectrum (d) contains the best-fitting model for spectrum a, which is composed of a parameterized spectrum of normal background and residual water signals (e) as well as the parameterized spectrum of Phe (f). Trace (g) contains the residuals of the best fit (i.e., a–d) for this case.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts